← board
ENGN
enGene, Inc.distress 1/10 · well-funded / low risk$1.82-1%today-85% from 52w high
Oncology 1
Lead: BCG-unresponsive NMIBC with CIS
Revenue
pre-revenue
Liquidity
$285M
Runway
2.6 yrs
Shares 1y
+31%
Price & events
-82.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-5.0%
1W
+6.7%
1M
-77.6%
3M
-85.0%
6M
-52.1%
1Y
-79.0%
2Y
—
5Y
-81.5%
All
Overview
- Market Cap
- $122.19M
- Volume
- 68.57K
- 52 Week Range
- $1.44 – $12.17
- Total Shares
- 66.99M
- Float Shares
- 22.49M
- Short %
- 2.10%
- % Held by Insiders
- 0.09%
- % Held by Institutions
- 100.24%
- RVOL
- 0.07x
- Beta
- -0.28
Pipeline stages · 1 programs
EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06-30 | Phase 1/2 | EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 ( | Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | 350 | recruiting |
Catalyst news & presentations · 8
- 2027regulatory submissionFiled (NDA/BLA)detalimogene · Potential BLA submission to FDASEC 8-K
- 2H 2026readoutPhase 2detalimogene · Top-line data from pivotal cohort of LEGEND studySEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)detalimogene voraplasmid · Planned BLA submission to FDA for detalimogene voraplasmidSEC 8-K
- 2026-09-14Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026regulatory submissionFiled (NDA/BLA)detalimogene voraplasmid · BLA submission for detalimogeneSEC 8-K
- May 15, 2026conferencedata presentationsecondarydetalimogene · Plenary presentation at AUA meeting.SEC 8-K
- 4Q 2025readoutPhase 2detalimogene voraplasmid · Update from LEGEND pivotal cohort.SEC 8-K
- 2024-10-24partnershipPrivate placement of 6,758,311 common shares at $8.90 per share, expected gross proceeds ~$60M, expected close Oct 29, 2024.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 66,989,466 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $3 (+80% upside) · 7 analysts
- 2026-06-18Morgan StanleyEqual-Weight → Underweight
- 2026-06-16HC Wainwright & Co.Buy
- 2026-05-14UBSNeutral
- 2026-05-08Wells FargoOverweight → Equal-Weight
- 2026-05-08Piper SandlerOverweight → Neutral
- 2026-05-08HC Wainwright & Co.Buy
Competitors — BCG-unresponsive NMIBC with CIS
Recent news
- 2026-07-22Executive options at enGene Therapeutics (ENGN) vesting over 4 years - Stock Titan
- 2026-07-22enGene Therapeutics (NASDAQ: ENGN) outlines insider RSUs and options - Stock Titan
- 2026-07-22enGene Therapeutics (ENGN) sees 5.0% beneficial stake reported by Acorn group - Stock Titan
- 2026-07-18enGene Holdings appoints new chairman to guide growth - The Globe and Mail
- 2026-07-17EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
- 2026-07-17enGene names Michael Heffernan board chairman as Richard Glickman steps down - Bitget
- 2026-07-16enGene appoints Michael Heffernan as board chairman - Investing.com
- 2026-07-16enGene appoints Michael Heffernan as board chairman By Investing.com - Investing.com Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.